Last reviewed · How we verify

NCT06763887

Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population

Completed Last updated 8 January 2025
What this trial tests

trial testing No Interventions in COVID in 100 participants. Completed in 30 June 2024.

Timeline
15 November 2023
Primary endpoint
30 June 2024
30 June 2024

Quick facts

Lead sponsorXijing Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date15 November 2023
Primary completion30 June 2024
Estimated completion30 June 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xijing Hospital

Who can join

Adults 18 to 75, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the immunogenicity and immune protection of COVID-19, especially the recently prevalent strains, against the background of current immunization in Chinese population

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No Interventions

Trials testing the same drug.

Other recruiting trials for COVID

Currently open trials in the same condition.

Other Xijing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing